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EGF MODULE-CONTAINING MUCIN-LIKE HORMONE RECEPTOR 2  AND 
ITS ROLE IN HUMAN IMMUNE PRIVILEGE 
HELEN SONG 
ABSTRACT 
 
Purpose: In the mouse, the macrophage adhesion G protein-coupled receptor 
(ad-GPCR) molecule, F4/80, is required for the development of regulatory T cells 
in two models of tolerance, the eye and gut. Since F4/80 is not expressed in 
humans, the purpose of this research is to determine the human analog of F4/80. 
F4/80 belongs to a novel family of Epidermal growth factor-seven 
transmembrane (EGF-TM7) molecules, which include the EGF module-
containing mucin-like hormone receptor (EMR) molecules. In the human, EMR1 
has sequential homology with F4/80 and EMR2 has shown immune suppressing 
function in tumor cells. Thus, we investigate the possible suppressor role of the 
EMR family in human ocular tolerance.  
Methods: Human peripheral blood mononuclear cells (huPBMC) were treated 
with porcine TGFβ2 and LPS or an antigenic stimulant for at least six hours to 
generate tolerogenic antigen presenting cells (APC). Cells were characterized by 
flow cytometric analysis for expression of CD14, CD40, PDL1, ILT3, and EMR2. 
Later, T regulatory cells were generated by incubating tolerogenic APCs with 
autologous huPBMC for five to seven days. Post culture, the T cells were stained 
and characterized for expression of CD4, CD25, and FoxP3.  
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Results: Post treatment of huPBMC with TGFβ2 and antigen, the resulting 
tolerogenic APCs expressed PDL1, ILT3, and EMR2. CD40 remained 
unchanged and CD14 was constitutively expressed. Post five to seven day 
culture, tolerogenic APCs treated with TGFβ2 increased the CD4+ CD25+ FoxP3+ 
lymphocyte populations.  
Conclusions: The upregulation of EMR2 on human tolerogenic APCs suggests 
that EMR2 may have a role in inducing tolerance in humans. Much like its mouse 
counterpart, F4/80, EMR2 is an adhesion molecule that may facilitate the 
induction of naïve T lymphocytes to regulatory T lymphocytes. Once the F4/80 
analog is established for humans, novel therapies may be developed to interfere 
or encourage signaling in the treatment of tumors or immune inflammatory 
diseases, respectively.  
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INTRODUCTION 
 
 As the essential organ providing vision to living animals, eyes are critical 
to observing and analyzing the world around us. In the human, the eye is 
composed of three translucent layers: the fibrous externa, the inner nervous 
retina, and the middle vascular tunic. Within this middle layer lies the anterior 
chamber, filled with aqueous humor. The anterior chamber primarily regulates 
intraorbital pressure; however, the aqueous humor also contributes to the eye’s 
unique ability to manipulate immunologic responses. Considering the immediate 
juxtaposition of the ocular surface to the outside world, the absence of recurrent 
immune reactions is paradoxical. Yet, the eye displays an important trait called 
ocular immune privilege, which allows it to coexist with the external environment 
without immune collateral damage (Abbas & Lichtman, n.d.). Many of the eye’s 
cells are permanent resident cells that rarely undergo regeneration. Thus, 
inflammation and its products could be irreversibly damaging and counteractive 
for the survival of the eye (Stein-Streilein & Lucas, 2011).  
 The lack of well-defined lymphatic drainage from the eye and its blood-
ocular barrier render it virtually isolated from the rest of the body in terms of 
immunologic surveillance. Immune privilege is very resilient and only transiently 
abrogated by infection, inflammation, or exogenous LPS. However, when the eye 
was subject to an injurious event, such as a retinal laser burn injury, immune 
privilege was lost and inflammation occurred (Lucas, Karamichos, Mathew, 
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Zieske, & Stein-Streilein, 2012). The autoantigens released have never been 
exposed to the body’s T lymphocytes, thus they are viewed as foreign and 
subsequent immune responses can mount against the eye causing conditions 
like uveitis, sympathetic ophthalmia, and in some cases progress to blindness 
(Shao et al., 2007; Stein-Streilein & Lucas, 2011). On the contrary, introduction of 
a foreign antigen or alloantigen into the eye induces the ocular immune privilege 
response and an active suppression of inflammatory processes is observed 
(Forrester & Xu, 2012).  
 So how, then, does the eye evade excessive inflammation and display 
immune privilege? Immune privilege in the eye presents both conserved and 
unique mechanisms of tolerance. Soluble Fas ligand within the eye plays a role 
in limiting inflammatory activity by binding to Fas receptors on infiltrating immune 
cells and activating apoptosis (Gregory et al., 2011). Also, the blood-ocular 
barrier helps to physically reduce the number of incoming immunogenic cells. 
Inherently, the anterior chamber houses immunosuppressive factors that bathe 
ocular immune cells. These factors include alpha melanocyte stimulating 
hormone, neuropeptide Y, pigment epithelial growth factor, and many others that 
actively keep immune cells in check (Taylor, 2007). Of interest, transforming 
growth factor beta (TGFβ), a cytokine known for promoting suppression of 
immune reactions, primes antigen presenting cells (APC) to change their function 
when come into contact with foreign antigen (D’Orazio & Niederkorn, 1998; 
Takeuchi et al., 2006).  
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Anterior Chamber Associated Immune Deviation 
 The Streilein group published extensive results that show if a foreign 
antigen is placed into the anterior chamber of a mouse eye, systemic tolerance to 
that antigen occurs. To study this process, a model called anterior chamber 
associated immune deviation (ACAID) was developed. This model showed that  
antigen in the presence of anterior chamber soluble factors triggers ocular APC 
to induce the regulatory phenotype in peripheral T lymphocytes (Streilein, Masli, 
Takeuchi, & Kezuka, 2002). These T regulatory cells then actively suppress 
immune reactions against the presented antigen. Critical to this process, a 
molecule known as F4/80 is upregulated on mouse APCs in response to TGFβ 
and antigen treatment (Lin et al., 2005; Willbanks et al., 1997). It appears that 
once the antigen is placed into the eye, it is picked up by F4/80+ cells that then 
leave the eye and travel to the marginal zone of the spleen where they cluster 
and interact with resting T lymphocytes, marginal zone B cells, and NKT cells 
(Faunce, Sonoda, & Stein-Streilein, 2001; Sonoda et al., 2001; Streilein & 
Niederkorn, 2007). In the absence of the F4/80 adhesion molecule, peripheral 
tolerance is not induced via the eye, nor are T regulatory cells induced in vitro. 
This correlates with the above outlined ACAID model (Lin et al., 2005). Inducible, 
now regulatory, T cells begin to express FoxP3 and cluster of differentiation 
(CD)25 (T regulatory cell markers) in addition to constitutively expressing CD4 or 
CD8, T helper or Cytotoxic T markers respectively (Ji, Yin, & Yang, 2011). With 
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this phenotype, the inflammatory processes are downregulated in an antigen-
specific fashion (Schmitt & Williams, 2013).  
 ACAID is a cooperation of the blood-ocular tight junction barrier, soluble 
factors of the anterior chamber, the tolerogenic F4/80+ APC, the spleen, and 
peripheral induced T regulatory cells, outlined by Figure 1.  
 
 
 
Figure 1. Synergistic processes of the ocular immune system. The ocular 
immune system includes multi-faceted defense mechanisms. Physical barriers, 
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anti-inflammatory mediators, suppressive cell and humoral immunologic factors 
are among many contributors to ocular immune privilege (used with permission, 
Stein-Streilein, 2006). 
 As an experimental model outlined by Kaplan, JW Streilein, and 
Niederkorn (1977, 1978; 1983; 2007), ACAID is induced in mice by injecting a 
common antigen such as OVA (chicken ovalbumin) directly into the anterior 
chamber of the eye. Seven days post anterior chamber inoculation, the mouse 
was deliberately immunized with the same antigen and CFA. An additional seven 
days later, the mouse was challenged with antigen into the ear pinnae. The 
following day, the swelling of the ear was measured. This swelling response is 
known as a delayed type hypersensitivity response (DTH), a cell-mediated 
reaction in which CD4+ T helper cells recognize major histocompatibility complex 
(MHC) class II - antigen complexes on APC. The CD4+ cells proliferate, releasing 
interleukin (IL)-2 and interferon-gamma (IFN-γ) to potentiate inflammatory 
responses. In the mice with functional F4/80, the ear swelling is minimal since 
ACAID has been evoked and the delayed hypersensitivity response is controlled. 
However in the same experimental conditions without functional F4/80, ear 
swelling is significant as T regulatory cells were not induced by ACAID and 
immune responses prevail (Lin et al., 2005).  
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EGF Module-Containing Mucin-Like Receptor 2 (EMR2) 
 While extensive work on characterizing the ocular immune 
microenvironment has been done in the mouse, little progress has been made 
translating the molecular mechanisms to the human. Largely in part, F4/80 is a 
specific mouse macrophage marker not present in humans. Understanding the 
molecules that facilitate the induction of T regulatory cells is crucial in defining 
tolerance in the human.  
 F4/80 is an adhesion G protein-coupled receptor (ad-GPCR) belonging to 
a subfamily called epidermal growth factor-seven transmembrane receptors 
(EGF-TM7). This family also includes a molecule called EGF-like module 
containing mucin-like hormone receptor (EMR). There are four known types of 
EMR, molecules 1-4. EMR 1, 2, and 3, as well as another EGF-TM7 molecule, 
CD97, map to the same region of the human chromosome 19p13 (Lin, Stacey, 
Hamann, Gordon, & McKnight, 2000). F4/80 maps to a synonymous region in the 
mouse genome.  
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Figure 2. Molecular structures of three largest EGF-TM7 molecules. The 
basic skeleton of EGF-TM7 molecules is conserved throughout the subfamily. 
Triangles with “E” represent the EGF-like domains, darkened circles denote N-
glycosylation sites, bars with no darkened circles represent known O-linked 
sugars. The absence of O-linked sugars on EMR1 and CD97 indicates these 
structures have not yet been studied. (Figure adapted from McKnight & Gordon, 
1998)  
As diagrammed by Figure 2, EMR1 is the structural homolog of F4/80 in the 
human (Hamann et al., 2007). With similar numbers of EGF-like domains, EMR, 
like F4/80, facilitates cell-cell adhesion. While the molecular structure has been 
determined, not much is known concerning the function of EMR1. While EMR1 
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may seem like the obvious F4/80 counterpart in the human, Hamann et al. (2007) 
have found EMR1 is a molecule specific for human eosinophils, co-expressed 
with CCR3 and immunoglobulin-like lectin Siglec-8. Thus, other EMR molecules 
were explored as a possibility of an F4/80 analog.  
 EMR3 is an EGF-TM7 molecule with only two EGF-like domains, as 
opposed to F4/80’s seven domains and EMR1’s six domains (Stacey, Lin, 
Hilyard, Gordon, & McKnight, 2001). While highly expressed on human myeloid 
cells, considerably neutrophils, monocytes, and macrophages, they only facilitate 
myeloid-myeloid adhesion interactions (Stacey et al., 2001). Important in other 
immune responses, EMR3 is unlikely to be a molecule required for the induction 
of ocular immune privilege due to its lack of myeloid-lymphoid binding ability.  
 Little is known about human EMR4. There has been work detailing two 
alternatively spliced human EMR4 transcripts, which are strikingly similar to the 
mouse in regards to the intron positions (Caminschi et al., 2006). Although the 
genetic sequences of EMR4 contain highly conserved regions similar to other 
EGF-TM7 family members, Caminschi et al. propose that expression of the TM7 
domain proteins is likely lost. While genetic analysis has been done, translation 
of EMR4 into a stable protein has not yet been detected (“EMR4P egf-like 
module containing, mucin-like, hormone receptor-like 4 pseudogene [Homo 
sapiens (human)] - Gene - NCBI,” n.d.). Thus, the function of EMR4 is still 
unknown. 
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 Lastly, EMR2 is the final EMR molecule of the EGF-TM7 subfamily. More 
extensively studied, it has been shown that EMR2 and its family member CD97 
are highly conserved in terms of their molecular structure (Lin et al., 2000; 
McKnight & Gordon, 1998). CD97, found constitutively on most immune cells of 
hematopoietic origin, is upregulated following immunogenic activation of 
lymphocytes (Abbott et al., 2007). Lin et al. (Lin et al., 2000) have highlighted the 
identical gene organization of EMR2 and CD97 to conclude that the two genes 
likely resulted from duplication. However, the two proteins do not share major 
cellular binding ligands. While CD97 is well known to interact with CD55 to 
regulate the complement cascade, EMR2 has a binding affinity to CD55 many-
fold lower than CD97 and thus postulated to have a different function and 
signaling pathway from CD97 (Lin et al., 2000). More recently, EMR2 has been 
found to be expressed in human breast tumor cells (Davies et al., 2011). The 
prevalence of EMR2 in the survival of neoplastic epithelial cells indicates a role 
for evading or down-regulating immunogenic responses. With these factors 
combined and a known ligand to block EMR2 signaling (Stacey et al., 2003), 
EMR2 was chosen as the molecular target for establishing an F4/80 analog in 
the human.  
 Due to its highly conserved nature and purported immunosuppressive 
properties, we hypothesized that EMR2 functions as the human analog of F4/80. 
This suggests that the molecule will be upregulated on tolerogenic APCs and be 
critical in the induction of T regulatory cells.   
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Specific Aims 
 In this study, we hypothesize that EMR2 is the F4/80 analog in the human. 
We suggest that this molecule serves the same function as F4/80 in facilitating 
the development of CD4+ CD25+ FoxP3+ T regulatory cells and that its 
expression is critical for the function of the tolerogenic APCs. After the induction 
of these lymphocytes into T regulatory cells, they actively suppress immunologic 
responses to the specific antigen presented by the APC.  
We plan to test this hypothesis by the following aims: 
1) Compare and contrast the surface molecules on APC exposed to antigen 
with or without TGFβ to characterize the phenotype of APCs from the 
human after in vitro treatment.  
2) Test the ability of the human tolerogenic APC to induce T regulatory cells 
when co-cultured with naïve lymphocytes using the expression of 
immunosuppressive markers and functions to define the T regulatory cells. 
3) Determine the role of EMR2 in the development of T regulatory cells by 
blocking EMR2 signaling prior to analysis of FoxP3 expression from T 
regulatory cells 
We expect these experiments to show: 
1) EMR2 is upregulated in human APC post treatment with aqueous humor 
type immunosuppressive factors, TGFβ.  
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2) An increase of CD4+ CD25+ FoxP3+ lymphocyte populations post-
treatment with tolerogenic APCs. 
3)  Blocking EMR2 with a soluble ligand specific to EMR will prevent the 
induction of CD4+ CD25+ FoxP3+ T regulatory cells. 
By identifying a major molecular mechanism in ocular immune privilege, 
novel therapies may be developed to induce or abrogate immune privilege not 
only in the eye but also in the periphery to treat inflammatory or neoplastic 
diseases, respectively.  
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METHODS  
 
Collection of Human Blood Samples 
 Blood samples were purchased from the Massachusetts General Hospital 
Blood Transfusion Service donor pool. Human donor protocols were considered 
exempt and were in compliance as defined by Massachusetts Eye and Ear 
Infirmary Institutional Review Board procedures and in approval with Partners 
Subcommittee on Human Studies. 
 
Cell Isolation 
 Peripheral blood mononuclear cells (PBMC) were collected from anti-
coagulated Leukopacs and washed twice with RPMI-1640 (Lonza, Basel, 
Switzerland), supplemented with 1 mM sodium pyruvate (Invitrogen, Carlsbad, 
CA), 0.1 mM non-essential amino acids (Invitrogen, Carlsbad, CA), 100 U/mL 
Penicillin/Streptomycin (Invitrogen, Carlsbad, CA), and 10% fetal bovine serum 
(FBS) (Atlanta Biologicals, Flowery Branch, GA). Monocytes were enriched by 
depletion of non-monocyte cells with Negative Monocyte Isolation Kit II (Miltenyi 
Biotec, Auburn, CA). Monocyte purity (~90-95%) was assessed by fluorescence-
activated cell sorting (FACS) and analyzed for the constitutive CD14 monocyte 
surface marker (BD Pharmingen, San Diego, CA). 
 
	  13	  	  
Generation of Tolerogenic APC 
 Isolated cells were plated on sterile petri dishes (BD Falcon, Franklin 
Lakes, NJ) in serum-free culture medium, RPMI-1640 supplemented with 
Glutamax (Invitrogen, Carlsbad, CA), 1 mM sodium pyruvate, 0.1 mM non-
essential amino acids, 100 U/mL Penicillin/Streptomycin, 10 mM HEPES 
(Invitrogen, Carlsbad, CA), Insulin/Transferrin/Selenium (ITS) (Invitrogen, 
Carlsbad, CA), and 0.1% BSA (Sigma-Aldrich, St. Louis, MO). Cells were 
cultured with or without 1 ng/mL porcine TGFβ2 (R&D Systems, Minneapolis, 
MN) for at least six hours. Cells were then pulsed with or without tetanus toxoid 
(TT) antigen (List Biological Laboratories, Campbell, CA) in serum-free media 
and incubated overnight in 37°C, 5% CO2.  
 APC were analyzed by flow cytometry to confirm the expression of 
myeloid and tolerogenic markers. CD14 (constitutive on monocyte-derived cells), 
Immunoglobulin-like transcript 3 (ILT3, cell surface immunoglobulin that co-
ligates to APC stimulatory receptors to downregulate activation signals (Cella et 
al., 1997)), Programmed cell death 1 ligand 1 (PD-L1, well-known 
immunosuppressive ligand), and EMR2 were measured. Monoclonal antibodies 
to ILT3 and PD-L1 were purchased from eBioscience (San Diego, CA) and the 
monoclonal antibody to EMR2 was purchased from R&D Systems (Minneapolis, 
MN).  
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Induction of T Regulatory Cells 
 Tolerogenic APC were washed twice with serum-free media to remove all 
of the exogenously added TGFβ. Cells were then cultured with an autologous T 
cell sample, obtained by Human T cell Enrichment Columns (R&D Systems, 
Minneapolis, MN). Antigen is then reintroduced to the cell co-culture prior to 
incubation at 37°C, 5% CO2 for five days. Following the incubation period, the 
cells were detached from the dishes by incubating with cold 2mM EDTA solution 
in phosphate buffered saline (PBS) for 10-15 minutes. Co-culture cells were 
collected and immunostained for CD4 (T helper cell marker), CD25, and FoxP3 
(in conjunction, regulatory T cell markers). In parallel, cells were tested for 
functionality by measuring intracellular production of IFN-γ (pro-inflammatory 
cytokine) and IL-10 (anti-inflammatory cytokine). All antibody markers and 
intracellular staining kit were purchased from eBioscience.  
 
Blocking EMR2 Ligand Binding 
 Monocytes were cultured as outlined above. Soluble chondroitin sulfate 
from shark cartilage (Sigma-Aldrich, St. Louis, MO) was used to bind to EMR and 
block signaling at a concentration of 1.5 mg/mL. CD25 and FoxP3 expression as 
well as intracellular cytokine functionality was tested. 
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Humanized NOD SCID Mouse Model 
 Fresh human PBMC were collected and were injected into the peritoneal 
cavity 12-15 week old NOD. Cg-Prkdcscid Il2rgtm1Wjl/SzJ female mice (Jackson 
Laboratory). This humanized the SCID mice. The following day, mice were 
anesthetized with 120 mg/kg of Ketamine and 20 mg/kg of Xylazine. Equal 
volumes of TT at 0.5 ug/mL and Complete Freund’s Adjuvant (Sigma-Aldrich, St. 
Louis, MO) were mixed into an emulsion and 100 ul was injected subcutaneously 
on the nape of the mouse neck using a 19G needle. Seven days later, mice were 
anesthetized with 120 mg/kg of Ketamine and 20 mg/kg of Xylazine. The 
thickness of the mice ears was measured using an engineer’s micrometer 
(Mitutoyo). Then a volume of 10 ul consisting of either 5 x 105 fresh autologous 
PBMCs with 1 ug/mL TT or 2.5 x 105 fresh autologous PBMCs with 2.5 x 105 T 
regulatory cells with 1 ug/mL TT was injected intradermally into the ear pinnae. 
24 Hours later, mice were anesthetized with 120 mg/kg of Ketamine and 20 
mg/kg of Xylazine. The thickness of the same ear was measured by an 
engineer’s micrometer and compared to original thickness.  
 
Data Analyses 
 Flow cytometry data was collected on a BD LSR II via BD FACSDiva 
software. Flow cytometry data was analyzed using FlowJo software (Tree Star, 
Ashland, OR). All data were compiled and statistically analyzed using GraphPad 
Prism (GraphPad Software, La Jolla, CA).  For statistical analyses, *p ≤ 0.05, **p 
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≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001 Differences between two groups were 
considered significant at p ≤ 0.05. 
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RESULTS 
 
Surface Markers on Human Tolerogenic APC 
 When treated with aqueous humor factors, namely TGFβ2, mouse F4/80 
macrophages acquire the ability to induce T regulatory cells. When treated with 
TGFβ2, human APCs upregulate inhibitory co-receptors as opposed to classical 
co-stimulatory molecules, such as CD40 (data not shown). Here, we compared 
and contrasted the surface markers expressed on APCs post-exposure to TGFβ2 
and antigen. CD14 remained constitutively expressed on all cell treatment groups 
(Figure 3A). PD-L1, an inhibitory co-receptor, and ILT3, a novel 
immunosuppressive molecule, were significantly (p ≤ 0.05) upregulated in the 
presence of both TGFβ2 and antigen when compared to antigen or TGFβ2 alone 
(Figure 3D, 3B). The potential F4/80 analog, EMR2, was also upregulated 
(Figure 3C). Significance was assessed by one-way ANOVA for each cell surface 
marker. A difference between two groups was considered significant if p ≤ 0.05. 
Flow cytometric data showed differences in surface marker expression in 
comparison to unstained control (Figure 4). 
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Figure 3. Phenotypic profile of tolerogenic APC. Each bar shows the mean ± 
SEM of three repeats. Y-axis represents percent of cells positive for each marker 
given the treatment condition.   
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Figure 4. Flow Cytometric APC Marker Profiles. Representative graphs for  
the four markers stained on the human tolerogenic APCs. Red corresponds to 
the unstained control; blue, cells treated with antigen alone; green, cells treated 
with antigen and TGFβ2. TGFβ2 alone showed similar fluorescence intensities 
as antigen alone (data not shown). ILT3, PD-L1, EMR2 were analyzed on a 
gated CD14 population to ensure majority monocytic cells for analysis. Y-axis 
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depicts percentage of cells out of total monocyte population. X-axis shows the 
fluorescence intensity of surface marker staining to the unstained control.  
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Induced T Regulatory Cells 
 Post antigen inoculation into the anterior chamber of the mouse, F4/80+ 
APCs travel from the eye to the marginal zone of the spleen to facilitate cell 
aggregations. The interactions of cells within the aggregates induce T regulatory 
cells. To recreate the tolerance inducing environment for human cells, we 
essentially created a “spleen-in-a-dish” in which tolerogenic APCs were co-
cultured with whole peripheral lymphocytes from the same blood sample. These 
lymphocytes were collected on a human T cell column in which unwanted cells 
attach to immunoglobulin or anti-immunoglobulin coated glass beads within the 
column. The resulting elution contained an enriched CD3+ (a universal T cell 
marker) population. In the co-cultures, tolerogenic APC induced a population of 
CD25+ FoxP3+ lymphocytes. These non-adherent cells were collected and 
confirmed by surface staining the CD4 marker and analyzed for CD25 and FoxP3 
(Figure 5).  T regulatory cells also increased production of the anti-inflammatory 
cytokine, IL-10 and decreased production of the pro-inflammatory cytokine, IFN- 
γ, also shown by figure 4.  
 Flow cytometric analysis showed an increase of cells expressing both 
CD25 and FoxP3 from the cultures that contained the tolerogenic APC (Figure 
6A). In the presence of TGFβ and antigen, the number of cells producing 
intracellular IL-10 increased and the number of cells producing intracellular IFN- γ 
decreased (Figure 6B, 6C).  
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Since our organ of interest is the eye, and the eye is protected by a blood-
ocular barrier, we have used serum-free culture medium in all of our 
experiments. Also, serum contains known inhibitors of TGFβ. Previously tested 
by the Stein-Streilein group, serum interferes with the signaling of many 
immunosuppressive factors in the aqueous humor. Thus, each experiment was 
done without serum. However, once the tolerogenic APCs are generated, the 
induction of T regulatory cells can occur in complete medium because signals 
that lead to T regulatory generation involve cell-cell contact and are not affected 
by the presence of serum. Thus, some experiments were conducted in complete 
medium for the latter portion of the APC-lymphocyte co-culture.  
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Figure 5 Function of induced T regulatory cells. Intracellular staining for 
FoxP3, IFN-γ, and IL-10 of CD4+ gated lymphocytes post co-culture with 
tolerogenic APC. (A) CD4+ lymphocytes stained for surface CD25 and 
intracellular FoxP3. Each donor was repeated in duplicate. Y-axis represents 
percent total of cells positive for both CD25 and FoxP3 with regards to each 
treatment condition. (B, C) CD4+ CD25+ lymphocytes stained for intracellular IFN-
γ or IL-10. Y-axis represents percent total of cells positive for IFN-γ or IL-10. 
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Figure 6. Flow cytometric dot plots of intracellular protein production. All 
quadrant gates were created on unstained untreated single color control 
populations. Quadrant II, as referenced in the text, is the upper right area of each 
graph which reflects populations that immunostained positive for both 
allophycocyanin and phycoerythrin fluorochromes. (A) Cells shown are CD4+ 
lymphocytes, with TGFβ, and with or without antigen. Y-axis measures the CD25 
marker by allophycocyanin (APC-A) fluorochrome, X-axis measures the 
intracellular FoxP3 marker by phycoerythrin (PE-A) fluorochrome. Both axes 
measure fluorescence intensity. Quadrant II (upper right corner) of each graph 
represents the CD4+ CD25+ FoxP3+ population. (B) Cells shown are CD4+ CD25+ 
lymphocytes, with TGFβ, and with or without antigen. Y-axis measures 
intracellular IFN-γ cytokine by allophycocyanin fluorochrome, X-axis measures 
intracellular IL-10 cytokine by phycoerythrin fluorochrome. Both axes measure 
fluorescence intensity. Panel B is a representative plot of decreased IFN- γ 
production in the presence of antigen. (C) Cells shown are CD4+ CD25+ 
lymphocytes, with TGFβ, and with or without antigen. Y-axis measures 
intracellular IFN-γ cytokine by allophycocyanin fluorochrome, X-axis measures 
intracellular IL-10 cytokine by phycoerythrin fluorochrome. Both axes measure 
fluorescence intensity. Panel C is a representative plot of increased IL-10 
production in the presence of antigen. Control samples for untreated and antigen 
alone conditions not shown.  
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Blocking EMR2 Ligand Binding  
 It has been found that the common ligand for EMR2 is chondroitin sulfate 
glycosaminoglycans (GAG) (Stacey et al., 2003). To mediate cell interactions, 
EMR2 binds to chondroitin sulfate GAGs on the opposing cell. To block EMR2 
signaling and the induction of T regulatory cells, we added soluble chondroitin 
sulfate to the cell culture. We hypothesized saturating the culture with soluble 
chondroitin sulfate will competitively bind up available EMR2 molecules and 
subsequently block signaling from the APC to the lymphocytes.  
 We treated APC with soluble chondroitin sulfate (1.5 mg/mL) in the same 
conditions listed above. By using a dose curve, we found 1.5 mg/mL was the 
ideal concentration for saturating EMR2 receptors. Post co-culture with 
lymphocytes, we repeated surface and intracellular staining of lymphocytes to 
check for differences in FoxP3+ cells (Figure 7).  
 Figure 8 shows flow cytometry readouts of the effect of using soluble 
chondroitin sulfate in the APC culture. In both figure 7 and figure 8, we see no 
increase in CD25+ FoxP3+ cell populations when treated with antigen and TGFβ.  
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Figure 7. FoxP3 expression of T cells treated with soluble chondroitin 
sulfate. Intracellular staining of FoxP3, surface staining of CD25 on CD4+ gated 
lymphocytes post co-culture with tolerogenic APC.  Y-axis represents percent of 
total lymphocytes positive for FoxP3 and CD25. Donor was repeated in duplicate. 
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Figure 8. Flow cytometric EMR2 readout and dot plot post-soluble 
chondroitin sulfate treatment. Quadrant II, as referenced in the text, is the 
upper right area that reflects populations that immunostained positive of both 
APC-A and PE-A. (A) APC were cultured with antigen and with or without TGFβ. 
Both conditions received 1.5 mg/mL of soluble chondroitin sulfate from shark 
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cartilage. Red corresponds to the unstained control, blue corresponds to the APC 
experimental conditions. Y-axis represents percentage of cells out of total 
monocyte population, X-axis represents fluorescence intensity of EMR2 staining 
compared to the unstained control. (B) Dot plot of TT alone vs TT and TGFβ with 
both conditions receiving 1.5 mg/mL of soluble chondroitin sulfate. Cells gated 
are CD4+ lymphocytes; Y-axis measures CD25 by allophycocyanin fluorochrome 
and X-axis measures FoxP3 by phycoerythrin fluorochrome. Quadrant gates 
were created on unstained untreated single color controls. Control samples for 
untreated and TGFβ alone are not shown.  
  
	  34	  	  
In Vivo Model 
 Once T regulatory cells were induced by our generated tolerogenic APCs, 
we began using NOD SCID mice to implement an in vivo model. SCID mice are 
unable to undergo somatic recombination of their T cell receptor genes, thus they 
are unable to form unique genetic sequences on their T cell receptors that 
recognize a bounty of antigenic proteins. As a result, these mice lack functional 
and mature T and B cells. In these mice, we applied our experimental conditions 
by adding fresh human PBMC into the animal system. We immunized the animal 
against the antigen of interest. Seven days later, the animal was challenged with 
the same antigen with or without autologous T regulatory cells generated in vitro. 
The following day, ear-swelling representative of the DTH response, was 
measured. With human cells, we were able to induce ACAID in an 
immunocompromised mouse with tetanus toxoid. 
Compared to the control condition in which no T regulatory cells and no 
antigen were added, a large swelling response with the addition of TT antigen 
was observed. When TT antigen in the presence of autologous T regulatory cells 
was added to the animal, a significant decrease of swelling was observed. Thus, 
the in vitro generated T regulatory cells from EMR2+ APCs were able to suppress 
DTH inflammation in the mouse ear.  
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Figure 9. DTH response in humanized SCID mice. Each bar is mean ± SEM of 
3-5 animals per treatment condition. Y-axis shows the change in ear swelling in 
millimeters. X-axis shows experimental condition of mice in each group.  
  
	  36	  	  
DISCUSSION 	  
Immune privilege is a trait unique to certain parts of the body that are 
critical to life. In other areas exposed to the external environment or foreign 
antigens of the external environment, tolerance is necessary in order to keep 
excessive inflammation in check. The more we understand how the body 
regulates immune responses and induces tolerance, the possibility of 
manipulating characteristics of innate and adaptive immunity for therapeutic 
purposes becomes more plausible.  
 
Human Tolerogenic APC 
 We determined that like F4/80 in the mouse, EMR2 is upregulated in 
human tolerogenic APCs post-treatment with aqueous humor-type 
immunosuppressive factors, namely TGFβ. Different from tolerogenic APCs, 
professional APCs present antigen and initiate T cell activation and proliferation. 
These two cell types differ phenotypically most notably in their co-stimulatory 
machinery. Professional APCs consist of dendritic cells, macrophages, and some 
B-cell types. Of the many types of dendritic cells, those myeloid cells that 
participate in T cell activation express CD11c and CD1a on their surface, which 
are classic dendritic cell markers. The professional macrophages express Mac-3 
and CD11b. Both cell types constitutively display CD14, which indicate that they 
are of monocytic origin as well as the obligatory MHC class II and CD40 for co-
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stimulation of the T cell. In the delayed type hypersensitivity response, both will 
secrete IL-12.  
 In immune privilege, tolerogenic APCs are of interest. Upon interaction 
with T cells, these APCs will induce the regulatory T cell phenotype and no T cell 
activation and expansion will occur. On the tolerogenic APCs, similar surface 
markers are present such as CD40 and MHC class II. However, these APCs 
express inhibitory molecules that compete with co-stimulatory molecules to 
prevent T cell activation. These inhibitory molecules include PD-L1 and ILT3, 
which downregulate or counter activating signals. In the presence of upregulated 
inhibitory molecules, EMR2 is also upregulated. Thus, EMR2 may be a marker 
for human tolerogenic APCs. While we did not explicitly test for other classic 
macrophage or dendritic cell markers listed above, these cells were constitutively 
CD14 positive and differentiated into tolerogenic APCs by showing upregulated 
inhibitory molecules that would be expected on suppressive monocytic cells 
interacting with T cells.  
 Our finding that EMR2 is upregulated on these tolerogenic APCs is novel. 
As an adhesion G-protein coupled receptor, EMR2 is a member of the EGF-TM7 
subfamily and found on cells of myeloid origin. F4/80, also a member of the EGF-
TM7 subfamily, is upregulated on mouse macrophages in the same experimental 
conditions with TGFβ and antigen. As our proposed F4/80 analog, the 
upregulation of EMR2 suggests that it functions in a synonymous manner to 
F4/80. Both are adhesion molecules capable of binding to glycosaminoglycans 
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and we postulate that EMR2 has a significant role in cell-cell interactions. 
Through adhesion or signaling, EMR2 on the tolerogenic APCs may facilitate cell 
clustering with other T cells, B cells, and NKT cells to induce a T regulatory cell 
population, much like the role of F4/80.   
 
Functions of Human Tolerogenic APCs 
 Second, we showed that a population of CD4+ CD25+ FoxP3+ 
lymphocytes increased post-culture with tolerogenic APC. The increase of this 
lymphocyte population in the mouse requires the presence of F4/80 on 
tolerogenic macrophages. When resting lymphocytes come into contact with 
F4/80 macrophages, the macrophages induce a peripheral lymphocyte 
population into the T regulatory phenotype, CD25+ FoxP3+. Much like the mouse, 
human tolerogenic APCs with upregulated EMR2 induced a T regulatory cell 
population that were able to suppress inflammation due to a specific antigen in 
vivo.  
 The significance of these inducible T regulatory cells is that they 
perpetuate tolerance to an antigen of interest in the periphery. There are two 
types of T regulatory cells, natural and induced. While natural T regulatory cells 
develop naturally within the thymus through T cell receptor affinity selection, 
inducible ones do not and are subject to a multitude of conditions outside the 
thymus. Development of extrathymic inducible T regulatory cells can occur within 
instances of inflammation in which effector T cells as well as regulatory T cells 
	  39	  	  
are developed simultaneously in a primary immune response. However, in 
conditions sans inflammation, inducible T regulatory cells can develop by antigen 
presentation from tolerogenic APCs. It is this latter condition in which our APCs 
induced other autologous peripheral lymphocytes into a population of CD25+ 
FoxP3+ cells. Thus, by priming our tolerogenic APCs with an antigen of interest, 
we induced tolerance in peripheral lymphocytes to become inducible T regulatory 
cells. In a living organism, the significance of an increased peripheral inducible T 
regulatory cell population indicates a systemic tolerance to that antigen from 
aqueous humor-derived tolerogenic APCs. This corroborates to the previously 
established mouse model and is the first step in translating tolerance and the 
mechanisms of immune privilege from the mouse to the human.  
 
EMR2 and its Ligand, Chondroitin Sulfate Glycosaminoglycans (GAGs) 
 Lastly, we determined that blockade of EMR2 with a soluble ligand 
specific to EMR prevents the induction of CD4+ CD25+ FoxP3+ T regulatory cells. 
When F4/80 is blocked on mouse macrophages, they fail to produce T regulatory 
cells. When we blocked EMR2 ligand binding on human tolerogenic APCs, they 
similarly failed to produce T regulatory cells. From this, EMR2 is required for 
human tolerogenic APCs to induce a CD4+ CD25+ FoxP3+ T regulatory cell 
population. Without EMR2, peripheral tolerance cannot be induced to the antigen 
of interest because these T regulatory cells are not there to suppress 
inflammatory activity against that antigen. Thus the adhesion or signaling 
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between EMR2 from the APC and its glycosaminoglycan ligand on peripheral 
lymphocytes is necessary in order to produce T regulatory cells that uphold 
tolerance throughout the body.  
 This novel discovery opens up the possibility of manipulating mechanisms 
of immune privilege for future therapies. It is possible that EMR2 is a marker for 
tolerogenic APCs in the human. As a suppressor molecule, it is likely to be found 
in areas of the body displaying immune privilege. From a pathological standpoint, 
these are likely to be areas with neoplastic growth. As our immune system 
recognizes tumor cells and abnormal growths of tissue, the presence of 
molecules like EMR2 help the tumors survive by participating in tolerance 
induction and evading immune surveillance. Blocking EMR2 and its subsequent 
signaling could potentially assist self immune defenses against the tumor.  
 In contrast, hyperinflammation is a hallmark of many different diseases. As 
inflammatory products are damaging to cells and tissues within the area, immune 
regulation may need to be invoked to control excessive immune reactions. 
Augmenting EMR2 signaling through TGFβ may be protective because it will 
reduce inflammation and control damage to the surrounding tissues.  
.  Through next-generation solutions like gene therapy, we may be able to 
manipulate the EMR2 gene construct and subsequent expression in an area of 
interest in order to induce or target immune privilege. While this may be far in the 
future, it has been shown extensively by the Streilein and Stein-Streilein groups 
that in vitro generated tolerogenic APCs are able to retain their functionality when 
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reintroduced into a living organism. Generating tolerogenic cells in vitro and re-
educating immune cells to become regulatory before re-injecting them into the 
area of interest may be a near future method to target localized inflammation. 
TGFβ treatment into a local tissue may also have the same effect. Thus knowing 
that tolerogenic APCs express EMR2 may be a basis for future therapies 
regarding immune and inflammation-related diseases.   
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